Abstract
Invariant natural killer T (iNKT) cells are an attractive therapeutic target in autoimmune diseases, since they play a major role in immune regulation. iNKT cells recognize glycolipid antigens presented by CD1d molecules that resemble the non-polymorphic MHC class I protein. α-galactosylceramide (α-GalCer) isolated from marine sponge has long been used as a prototype iNKT cell ligand in the laboratory. As α-GalCer is the most efficacious ligand for iNKT cells, its potential to treat autoimmune disease has been evaluated in animal models. Previous studies showed that α- GalCer effectively suppressed disease in some autoimmunity models, but not in others. This inconsistency may be attributed to the ability of α-GalCer to induce the production of both proinflammatory Th1 and anti-inflammatory Th2 cytokines by iNKT cells. To overcome this issue, we and other groups have synthesized new, unnatural glycolipids by modifying the structure of α-GalCer. These efforts have led to an identification of glycolipid compounds that provoke the production of Th2 (but not Th1) cytokines by iNKT cells. Among these novel ligands, an α-GalCer analogue named OCH, which contains a truncated sphingosine chain, induces a Th2 biased response by murine iNKT cells. Here we describe that OCH also polarizes human iNKT cells towards Th2, which opens up a new avenue for the clinical application of glycolipid compounds in treating of autoimmune diseases such as multiple sclerosis. The pursuit of synthetic glycolipid antigens has the great potential to lead to a better understanding of the regulatory effects of human iNKT cells and development of a new therapeutic agent for autoimmune diseases.
Keywords: Glycolipid, synthetic α-galacotosylceramide analogues, autoimmune disease, iNKT cells, Th1-Th2
Current Medicinal Chemistry
Title: Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy
Volume: 15 Issue: 23
Author(s): Manabu Araki, Sachiko Miyake and Takashi Yamamura
Affiliation:
Keywords: Glycolipid, synthetic α-galacotosylceramide analogues, autoimmune disease, iNKT cells, Th1-Th2
Abstract: Invariant natural killer T (iNKT) cells are an attractive therapeutic target in autoimmune diseases, since they play a major role in immune regulation. iNKT cells recognize glycolipid antigens presented by CD1d molecules that resemble the non-polymorphic MHC class I protein. α-galactosylceramide (α-GalCer) isolated from marine sponge has long been used as a prototype iNKT cell ligand in the laboratory. As α-GalCer is the most efficacious ligand for iNKT cells, its potential to treat autoimmune disease has been evaluated in animal models. Previous studies showed that α- GalCer effectively suppressed disease in some autoimmunity models, but not in others. This inconsistency may be attributed to the ability of α-GalCer to induce the production of both proinflammatory Th1 and anti-inflammatory Th2 cytokines by iNKT cells. To overcome this issue, we and other groups have synthesized new, unnatural glycolipids by modifying the structure of α-GalCer. These efforts have led to an identification of glycolipid compounds that provoke the production of Th2 (but not Th1) cytokines by iNKT cells. Among these novel ligands, an α-GalCer analogue named OCH, which contains a truncated sphingosine chain, induces a Th2 biased response by murine iNKT cells. Here we describe that OCH also polarizes human iNKT cells towards Th2, which opens up a new avenue for the clinical application of glycolipid compounds in treating of autoimmune diseases such as multiple sclerosis. The pursuit of synthetic glycolipid antigens has the great potential to lead to a better understanding of the regulatory effects of human iNKT cells and development of a new therapeutic agent for autoimmune diseases.
Export Options
About this article
Cite this article as:
Araki Manabu, Miyake Sachiko and Yamamura Takashi, Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy, Current Medicinal Chemistry 2008; 15 (23) . https://dx.doi.org/10.2174/092986708785909184
DOI https://dx.doi.org/10.2174/092986708785909184 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design A Key Role for Altered Dendritic Cell Functioning in the Impaired Immunity Seen in Aged Individuals
Current Immunology Reviews (Discontinued) CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus
Current Rheumatology Reviews Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Modulation of the Immune Response by the Cholera-like Enterotoxins
Current Topics in Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Current Stem Cell Research & Therapy CCL17/Thymus and Activation-Related Chemokine: A biomarker for Churg-Strauss Syndrome?
Current Biomarkers (Discontinued) Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Survival Factors from Activated Accessory Cells and their Role in Triggering Autoimmune Diseases
Current Medicinal Chemistry Transglutaminases as Targets for Pharmacological Inhibition
Mini-Reviews in Medicinal Chemistry Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research